315 related articles for article (PubMed ID: 15029079)
21. Memantine in the treatment of mild-to-moderate Alzheimer's disease.
Cosman KM; Boyle LL; Porsteinsson AP
Expert Opin Pharmacother; 2007 Feb; 8(2):203-14. PubMed ID: 17257090
[TBL] [Abstract][Full Text] [Related]
22. [Memantine (Ebixa), glutaminergic modulator].
Sternon J; Bier JC
Rev Med Brux; 2004 Apr; 25(2):93-7. PubMed ID: 15157062
[TBL] [Abstract][Full Text] [Related]
23. Pathologically-activated therapeutics for neuroprotection: mechanism of NMDA receptor block by memantine and S-nitrosylation.
Lipton SA
Curr Drug Targets; 2007 May; 8(5):621-32. PubMed ID: 17504105
[TBL] [Abstract][Full Text] [Related]
24. Memantine hydrochloride: pharmacological and clinical profile.
Möbius HJ; Stöffler A; Graham SM
Drugs Today (Barc); 2004 Aug; 40(8):685-95. PubMed ID: 15510240
[TBL] [Abstract][Full Text] [Related]
25. [New options for the pharmacotherapy of Alzheimer's disease after the registration of memantine?].
Frölich L; Schmitt B; Calabrese P; Diener H; Förstl H; Gertz HJ; Hallauer JF; Hampel H; Ihl R; Rieke K; Riepe M; Supprian T
Dtsch Med Wochenschr; 2005 Feb; 130(8):408-12. PubMed ID: 15717252
[No Abstract] [Full Text] [Related]
26. N-methyl D-aspartate (NMDA) receptor antagonists and memantine treatment for Alzheimer's disease, vascular dementia and Parkinson's disease.
Olivares D; Deshpande VK; Shi Y; Lahiri DK; Greig NH; Rogers JT; Huang X
Curr Alzheimer Res; 2012 Jul; 9(6):746-58. PubMed ID: 21875407
[TBL] [Abstract][Full Text] [Related]
27. Memantine: a therapeutic approach in treating Alzheimer's and vascular dementia.
Koch HJ; Uyanik G; Fischer-Barnicol D
Curr Drug Targets CNS Neurol Disord; 2005 Oct; 4(5):499-506. PubMed ID: 16266284
[TBL] [Abstract][Full Text] [Related]
28. Memantine: a pharmacoeconomic review of its use in moderate-to-severe Alzheimer's disease.
Plosker GL; Lyseng-Williamson KA
Pharmacoeconomics; 2005; 23(2):193-206. PubMed ID: 15748093
[TBL] [Abstract][Full Text] [Related]
29. Analysis of the effect of memantine in reducing the worsening of clinical symptoms in patients with moderate to severe Alzheimer's disease.
Wilkinson D; Andersen HF
Dement Geriatr Cogn Disord; 2007; 24(2):138-45. PubMed ID: 17622761
[TBL] [Abstract][Full Text] [Related]
30. Memantine.
Jarvis B; Figgitt DP
Drugs Aging; 2003; 20(6):465-76; discussion 477-8. PubMed ID: 12710865
[TBL] [Abstract][Full Text] [Related]
31. Rationale for combination therapy with galantamine and memantine in Alzheimer's disease.
Grossberg GT; Edwards KR; Zhao Q
J Clin Pharmacol; 2006 Jul; 46(7 Suppl 1):17S-26S. PubMed ID: 16809811
[TBL] [Abstract][Full Text] [Related]
32. Memantine treatment in mild to moderate Alzheimer disease: a 24-week randomized, controlled trial.
Peskind ER; Potkin SG; Pomara N; Ott BR; Graham SM; Olin JT; McDonald S
Am J Geriatr Psychiatry; 2006 Aug; 14(8):704-15. PubMed ID: 16861375
[TBL] [Abstract][Full Text] [Related]
33. Pharmacotherapeutic approaches to the treatment of Alzheimer's disease.
Standridge JB
Clin Ther; 2004 May; 26(5):615-30. PubMed ID: 15220008
[TBL] [Abstract][Full Text] [Related]
34. A 24-week randomized, controlled trial of memantine in patients with moderate-to-severe Alzheimer disease.
van Dyck CH; Tariot PN; Meyers B; Malca Resnick E;
Alzheimer Dis Assoc Disord; 2007; 21(2):136-43. PubMed ID: 17545739
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of memantine for the treatment of Alzheimer's disease.
Ferris SH
Expert Opin Pharmacother; 2003 Dec; 4(12):2305-13. PubMed ID: 14640929
[TBL] [Abstract][Full Text] [Related]
36. Benefits of combined cholinesterase inhibitor and memantine treatment in moderate-severe Alzheimer's disease.
Gauthier S; Molinuevo JL
Alzheimers Dement; 2013 May; 9(3):326-31. PubMed ID: 23110864
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300).
Orgogozo JM; Rigaud AS; Stöffler A; Möbius HJ; Forette F
Stroke; 2002 Jul; 33(7):1834-9. PubMed ID: 12105362
[TBL] [Abstract][Full Text] [Related]
38. Pooled analyses on cognitive effects of memantine in patients with moderate to severe Alzheimer's disease.
Emre M; Mecocci P; Stender K
J Alzheimers Dis; 2008 Jun; 14(2):193-9. PubMed ID: 18560130
[TBL] [Abstract][Full Text] [Related]
39. Pharmacoeconomic aspects of memantine (Ebixa) in the treatment of Alzheimer's disease.
Wimo A
Expert Rev Pharmacoecon Outcomes Res; 2003 Dec; 3(6):675-80. PubMed ID: 19807344
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
